253 related articles for article (PubMed ID: 19800368)
21. The Antimalarial Compound Atovaquone Inhibits Zika and Dengue Virus Infection by Blocking E Protein-Mediated Membrane Fusion.
Yamamoto M; Ichinohe T; Watanabe A; Kobayashi A; Zhang R; Song J; Kawaguchi Y; Matsuda Z; Inoue JI
Viruses; 2020 Dec; 12(12):. PubMed ID: 33371476
[TBL] [Abstract][Full Text] [Related]
22. 3-O-sulfated glucuronide derivative as a potential anti-dengue virus agent.
Hidari KI; Ikeda K; Watanabe I; Abe T; Sando A; Itoh Y; Tokiwa H; Morita K; Suzuki T
Biochem Biophys Res Commun; 2012 Aug; 424(3):573-8. PubMed ID: 22776202
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel target sites and an inhibitor of the dengue virus E protein.
Yennamalli R; Subbarao N; Kampmann T; McGeary RP; Young PR; Kobe B
J Comput Aided Mol Des; 2009 Jun; 23(6):333-41. PubMed ID: 19241120
[TBL] [Abstract][Full Text] [Related]
24. Peptide inhibitors against dengue virus infection.
Panya A; Bangphoomi K; Choowongkomon K; Yenchitsomanus PT
Chem Biol Drug Des; 2014 Aug; 84(2):148-57. PubMed ID: 24612829
[TBL] [Abstract][Full Text] [Related]
25. Identification of a small-molecule inhibitor of dengue virus using a replicon system.
Hsu YC; Chen NC; Chen PC; Wang CC; Cheng WC; Wu HN
Arch Virol; 2012 Apr; 157(4):681-8. PubMed ID: 22249364
[TBL] [Abstract][Full Text] [Related]
26. Identification and characterization of prohibitin as a receptor protein mediating DENV-2 entry into insect cells.
Kuadkitkan A; Wikan N; Fongsaran C; Smith DR
Virology; 2010 Oct; 406(1):149-61. PubMed ID: 20674955
[TBL] [Abstract][Full Text] [Related]
27. Heparan sulfate proteoglycans initiate dengue virus infection of hepatocytes.
Hilgard P; Stockert R
Hepatology; 2000 Nov; 32(5):1069-77. PubMed ID: 11050058
[TBL] [Abstract][Full Text] [Related]
28. Entry of hepatitis delta virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulfide exchange.
Abou-Jaoudé G; Sureau C
J Virol; 2007 Dec; 81(23):13057-66. PubMed ID: 17898062
[TBL] [Abstract][Full Text] [Related]
29. Discovery of novel small molecule inhibitors of dengue viral NS2B-NS3 protease using virtual screening and scaffold hopping.
Deng J; Li N; Liu H; Zuo Z; Liew OW; Xu W; Chen G; Tong X; Tang W; Zhu J; Zuo J; Jiang H; Yang CG; Li J; Zhu W
J Med Chem; 2012 Jul; 55(14):6278-93. PubMed ID: 22742496
[TBL] [Abstract][Full Text] [Related]
30. Differences between cell membrane fusion activities of two dengue type-1 isolates reflect modifications of viral structure.
Desprès P; Frenkiel MP; Deubel V
Virology; 1993 Sep; 196(1):209-19. PubMed ID: 8356794
[TBL] [Abstract][Full Text] [Related]
31. The use of a quantitative fusion assay to evaluate HN-receptor interaction for human parainfluenza virus type 3.
Levin Perlman S; Jordan M; Brossmer R; Greengard O; Moscona A
Virology; 1999 Dec; 265(1):57-65. PubMed ID: 10603317
[TBL] [Abstract][Full Text] [Related]
32. Novel binding between pre-membrane protein and claudin-1 is required for efficient dengue virus entry.
Gao F; Duan X; Lu X; Liu Y; Zheng L; Ding Z; Li J
Biochem Biophys Res Commun; 2010 Jan; 391(1):952-7. PubMed ID: 19962368
[TBL] [Abstract][Full Text] [Related]
33. Hijacking the Fusion Complex of Human Parainfluenza Virus as an Antiviral Strategy.
Marcink TC; Yariv E; Rybkina K; Más V; Bovier FT; des Georges A; Greninger AL; Alabi CA; Porotto M; Ben-Tal N; Moscona A
mBio; 2020 Feb; 11(1):. PubMed ID: 32047132
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates.
Bernardo L; Izquierdo A; Alvarez M; Rosario D; Prado I; López C; Martínez R; Castro J; Santana E; Hermida L; Guillen G; Guzmán MG
Antiviral Res; 2008 Nov; 80(2):194-9. PubMed ID: 18602424
[TBL] [Abstract][Full Text] [Related]
35. Antiviral activity of membrane fusion inhibitors that target gp40 of the feline immunodeficiency virus envelope protein.
Mizukoshi F; Baba K; Goto Y; Setoguchi A; Fujino Y; Ohno K; Oishi S; Kodera Y; Fujii N; Tsujimoto H
Vet Microbiol; 2009 Apr; 136(1-2):155-9. PubMed ID: 19036536
[TBL] [Abstract][Full Text] [Related]
36. High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli.
Jaiswal S; Khanna N; Swaminathan S
Protein Expr Purif; 2004 Jan; 33(1):80-91. PubMed ID: 14680965
[TBL] [Abstract][Full Text] [Related]
37. [Recombinant envelope glycoprotein domain III of dengue virus inhibit virus infection].
Lu P; Wei Y; Cao SC; Li JD; Liu QZ; Zhang QF; Li C; Miao F; Zhang S; Hang XT; Liang MF; Li DX
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Jun; 22(3):177-9. PubMed ID: 19031695
[TBL] [Abstract][Full Text] [Related]
38. U18666A, an intra-cellular cholesterol transport inhibitor, inhibits dengue virus entry and replication.
Poh MK; Shui G; Xie X; Shi PY; Wenk MR; Gu F
Antiviral Res; 2012 Jan; 93(1):191-8. PubMed ID: 22146564
[TBL] [Abstract][Full Text] [Related]
39. Small-molecule inhibitors of dengue-virus entry.
Schmidt AG; Lee K; Yang PL; Harrison SC
PLoS Pathog; 2012; 8(4):e1002627. PubMed ID: 22496653
[TBL] [Abstract][Full Text] [Related]
40. Structure-based drug design for envelope protein E2 uncovers a new class of bovine viral diarrhea inhibitors that block virus entry.
Pascual MJ; Merwaiss F; Leal E; Quintana ME; Capozzo AV; Cavasotto CN; Bollini M; Alvarez DE
Antiviral Res; 2018 Jan; 149():179-190. PubMed ID: 29031833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
